Tuesday, 22 Oct 2019

You are here

Skin Cancer Risk in ANCA+ Vasculitis

Previously, granulomatous polyangitis (GPA or Wegener's) was known to have an increase risk of cancer, especially bladder cancer, presumeably due to cyclophosphamide (CTX) exposure. With the change in nomenclature comes uncertainty about the risk of cancer in those with ANCA-associated vasculitis (AAV).

Dutch researchers have analyzed their cohort of histopathologically confirmed AAV, seen between 1991 and 2013 and followed for 10 years.

Neoplasia was found in 36/138 AAV patients (26% with a total of 85 malignancies). The adjusted malignancy risk was 2.21-fold higher than the general population.

The most common cancer was non-melanoma skin cancer (standardized incidence ratio 4.23 [95% CI 2.76–6.19]), but other malignancies were not significantly increased. CTX therapy was a significant risk factor but not in patients who had received CTX for <1 year.

This change in CTX-associated malignancy reflects ongoing efforts to reduce its use with other treatment regimens.

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Protective Effects of ASA and Vasodilators in Systemic Sclerosis

A large cohort study suggests that the use of vasodilators and aspirin (ASA) in systemic sclerosis (SSc) may yield favorable  cardiovascular outcomes.

Myositis Patients at High Risk of Opportunistic Infections

Among patients with systemic rheumatic diseases, the highest incidence of opportunistic infections was seen in those with polymyositis/dermatomyositis (PM/DM), Taiwanese researchers found.

Warfarin Superior to Xarelto in Antiphospholipid Syndrome

A 3 year, multicenter, European, study shows that rivaroxaban was inferior to warfarin in preventing thrombosis in patients with antiphospholipid syndrome (APS) according to the Annals of Internal Medicine. Thus despite the inconvenience of warfarin, it remains the best option for patients with APS.

Declining Trends in Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis Mortality in the USA

Annals of Internal Medicine reports that age-adjusted mortality rates for antineutrophil cytoplasmic autoantibody–associated vasculitides (AAV) have improved over time - with a decline of nearly 2 percent per year in the United States from 1999 to 2017. Nevertheless, long-term outcomes continue to lag behind mortality rates of the general population.

Serum Interferon Predicts Lupus Flares

Elevated serum levels of interferon-α among patients whose systemic lupus erythematosus (SLE) was in remission helped predict future disease flares, European researchers found.

Among 254 SLE patients who were in remission, 26% had abnormally high serum levels of interferon-α at baseline, according to Alexis Mathian, MD, of Pitié-Salpêtrière Hospital in Paris, and colleagues.